Amarin Corporation plc (AMRN) News
Track canonical SquawkNews coverage tagged to AMRN, Amarin Corporation plc. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 3 indexed stories across 3 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
AMRN - Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy
AMRN - Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence
EARNINGS | Jul 29, 2026, 11:01 AM UTC
H
serial disappointer risk (missed last qtr) in EPS reporters tonight and tomorrow morning - CGAU, OI, FCF, RCKY, RPT, APAM, GEHC, PB, VFC, OG
serial disappointer risk (missed last qtr) in EPS reporters tonight and tomorrow morning - CGAU, OI, FCF, RCKY, RPT, APAM, GEHC, PB, VFC, OGE, SITE, ARCC, BTU, STRA, MNRO, MCHB, RDWR, SHEN, AMRN
EARNINGS | Jul 28, 2026, 04:09 PM UTC
L
Amarin Highlights Recent FDA Approval Of Injectable Apolipoprotein C-III Therapies For Treatment Of Severe Hypertriglyceridemia, Defined As
Amarin Corporation plc (NASDAQ: AMRN ), a company committed to advancing the science of cardiovascular disease worldwide, applauds the recent FDA approval of injectable apolipoprotein C-III (APOC3) therapies for the trea
REGULATION | Jun 30, 2026, 08:18 PM UTC